Long-acting drugs for hemophilia have emerged that could reduce the need for regular intravenous infusions of blood clotting agents. Treatments such as Biogen's Alprolix and Novo Nordisk's investigational drug N9-GP could help cut the cost of existing treatments, according to industry experts. Biotech companies such as BioMarin Pharmaceutical and Sangamo BioSciences are working on gene therapies that could enable people with hemophilia to make their own clotting factor.
Long-acting treatments bring new hope to hemophilia patients
SmartBrief Job Listings for Health Care
|Sr. Medical Device Reimbursement Specialist - Regional||
|Fort Worth , TX|
|Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group||
|Clinical Trials Agreements Specialist (209955)||
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
|SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST||
Matheson Tri-Gas, Inc.
ASAHI INTECC, Orange County CA R&D Center
|Santa Ana, CA|